Cytosorbents Corp ((CTSO)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The Safe and Timely Antithrombotic Removal (STAR) Registry is an international observational study conducted by CytoSorbents Corp. Its primary aim is to document real-world clinical use and outcomes of the CytoSorb device, specifically for removing antithrombotic agents in acute hospital settings. This study is significant as it addresses critical conditions such as surgical and postoperative hemorrhage, providing insights into the device’s effectiveness and safety.
The intervention being tested is the CytoSorb device, a sorbent hemoperfusion system designed to remove antithrombotic agents from the bloodstream. This device aims to manage and mitigate bleeding risks in patients undergoing surgery or experiencing postoperative complications.
The STAR Registry is designed as an observational cohort study. It does not involve random allocation or masking, focusing instead on collecting data from real-world clinical settings to understand the device’s impact on patient outcomes. The primary purpose is to gather comprehensive data on the use of CytoSorb in managing blood loss and related complications.
The study began on September 9, 2021, and is currently recruiting participants. The latest update was submitted on July 15, 2025, indicating ongoing data collection and analysis. These dates are crucial for tracking the study’s progress and ensuring timely updates to stakeholders.
The update on the STAR Registry could influence CytoSorbents Corp’s stock performance by boosting investor confidence if the device demonstrates significant clinical benefits. As the healthcare industry increasingly focuses on innovative solutions for managing surgical complications, positive results from this study could position CytoSorbents favorably against competitors, potentially impacting market dynamics.
The STAR Registry is ongoing, with further details available on the ClinicalTrials portal.